NEXVIAZYME avalglucosidase alfa-ngpt for injection, 100mg vial (USA)
Section 19A approved medicine
NEXVIAZYME avalglucosidase alfa-ngpt for injection, 100mg vial (USA)
Section 19A approval holder
Sanofi-Aventis Australia Pty Ltd ABN 31 008 558 807
Phone
1800 818 806
Approved until
Status
Current
Medicines in short supply/unavailable
NEXVIAZYME avalglucosidase alfa powder for injection100mg vial - ARTG 346495
Indication(s)
Nexviazyme is indicated for long-term enzyme replacement therapy for the treatment of patients one year of age and older with Pompe disease (acid α-glucosidase deficiency).
Images
